In this report you can find an overview and analysis of the following:

• Induced pluripotent stem cell (iPSC) technology has the potential to transform the treatment landscape and bring curative options to patients. iPSC-derived cells have the potential to address a wide range of diseases and serve as a fertile ground for new investment opportunities
• Capital invested into the iPSC space has grown exponentially over the last ~5 years from $120M in 2016 to more than $2B in 2021.The number of financing deals during that period grew from a modest base of 4 to 35 with early-stage VC rounds accounting for ~56% of this volume
• Oncology has consistently been a key driver in both deal volume and total deal sizes in the iPSC space. Other indications like hepatology, hemoglobinopathies, immunology, CNS and endocrinology have also recently driven recent investments. Companies focused on hemoglobinopathies have been able to raise significantly more capital on a per deal basis
• Given the early stage of this technology, the iPSC space has seen few pure non-oncology IPOs and the greatest returns to investors have been realized by the earliest entrants. Within venture financings, Series A and B rounds have achieved the greatest returns.
• Strategic partnerships are also emerging as a source of non-dilutive funding for iPSC companies. While iPSC technologies targeting oncology indications have seen several $3B+ strategic transactions, non-oncology deals have only been able to obtain <$1B in total deal size
• Patent landscape analysis points to academic clusters with future source of new company investments. University of California has been more active with patents in the iPSC space, while Harvard University is the leading institution from which iPSC-related biotech companies are founded